Public trial registry of the CCC-Munich

Trial KEYNOTE 716

Trial Trial design Status In-/Exclusion Therapy Participants Documents Permissions Tumorboards

Trial
World
Trial acronym
:
KEYNOTE 716
World
Full title
:

AdjuvanteTherapie mit Pembrolizumab versus Placebo beim resezierten Hochrisikomelanom im Stadium II: eine randomisierte, doppelblinde Phase III Studie (KEYNOTE 716)

World
EudraCT number
:
World
NCT number
:
World
Responsible organization
:
Klinik f. Dermatologie/Allerg., Telefon: 089440056010
Indications
Classification Code Description
ICD-10-GM C43.9 Bösartiges Melanom der Haut, nicht näher bezeichnet
Trial design
World
Trial type
:
Interventional
World
Blinding type
:
Double blinded
World
Phase
:
III
Status
World
Status
:
Recruitment finished
Votes
World
Institutional review board - vote
:
Unknown
Initiiation & lock
World
Date of lock (planned / actual)
:
2033-10-12 / Unknown
Therapy
World
Therapy line
:
1
Participants
Function Prename Surname Organization
World Principal Investigator LUCIE HEINZERLING Keine Organisationseinheit angegeben Magnifier